RHJA
PBYI icon

Rice Hall James & Associates’s Puma Biotechnology PBYI Stock Holding History

Rice Hall James & Associates’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-144,792
Closed -$472K – 259
2024
Q2 		$472K Buy
144,792
+4,686
+3% +$20.6K 0.03% 236
2024
Q1 		$743K Sell
140,106
-189,764
-58% -$1.02M 0.04% 216
2023
Q4 		$1.43M Sell
329,870
-33,796
-9% -$112K 0.08% 201
2023
Q3 		$956K Sell
363,666
-7,368
-2% -$25.1K 0.06% 207
2023
Q2 		$1.31M Buy
371,034
+3,537
+1% +$11K 0.07% 200
2023
Q1 		$1.14M Sell
367,497
-15,721
-4% -$59.3K 0.06% 230
2022
Q4 		$1.62M Sell
383,218
-4,321
-1% -$14.9K 0.09% 208
2022
Q3 		$918K Sell
387,539
-118,527
-23% -$346K 0.05% 234
2022
Q2 		$1.44M Sell
506,066
-5,167
-1% -$12.8K 0.07% 218
2022
Q1 		$1.47M Buy
511,233
+19,951
+4% +$51.6K 0.06% 230
2021
Q4 		$1.49M Sell
491,282
-55,026
-10% -$239K 0.05% 228
2021
Q3 		$3.83M Buy
546,308
+692
+0.1% +$5.18K 0.14% 117
2021
Q2 		$5.01M Sell
545,616
-60,176
-10% -$610K 0.18% 94
2021
Q1 		$5.89M Buy
605,792
+855
+0.1% +$9.55K 0.19% 95
2020
Q4 		$6.21M Buy
604,937
+23,942
+4% +$242K 0.22% 86
2020
Q3 		$5.86M Buy
580,995
+125,428
+28% +$1.28M 0.24% 86
2020
Q2 		$4.75M Sell
455,567
-10,915
-2% -$113K 0.2% 114
2020
Q1 		$3.94M Sell
466,482
-44,374
-9% -$431K 0.22% 108
2019
Q4 		$4.47M Sell
510,856
-43,136
-8% -$357K 0.15% 122
2019
Q3 		$5.96M Sell
553,992
-4,897
-0.9% -$52.9K 0.21% 114
2019
Q2 		$7.1M Sell
558,889
-19,662
-3% -$453K 0.24% 118
2019
Q1 		$22.4M Buy
578,551
+112,241
+24% +$3.43M 0.72% 41
2018
Q4 		$9.49M Buy
466,310
+227,311
+95% +$6.82M 0.35% 95
2018
Q3 		$11M Buy
238,999
+64,242
+37% +$3.1M 0.39% 91
2018
Q2 		$10.3M Buy
174,757
+6,793
+4% +$394K 0.38% 92
2018
Q1 		$11.4M Buy
167,964
+61,692
+58% +$4.62M 0.45% 84
2017
Q4 		$10.5M Buy
106,272
+82,953
+356% +$9.28M 0.41% 88
2017
Q3 		$2.79M Sell
23,319
-780
-3% -$72.5K 0.12% 141
2017
Q2 		$2.11M Buy
+24,099
New +$1.35M 0.09% 186

Other funds holding PBYI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Rice Hall James & Associates's PBYI Position: Q3 2024 in Review

Rice Hall James & Associates sold out of Puma Biotechnology (PBYI) in Q3 2024, closing a stake of 144,792 shares — an estimated $472K sold.

Rice Hall James & Associates first reported a position in PBYI in Q2 2017 and held it in 29 quarters. The position peaked at $22.4M in Q1 2019. 100 funds tracked by Wall St. Rank hold PBYI as of Q3 2024.

  • Rice Hall James & Associates reported no remaining Puma Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Rice Hall James & Associates sold 144,792 Puma Biotechnology shares in Q3 2024, an estimated $472K.
  • Rice Hall James & Associates first reported a position in Puma Biotechnology in Q2 2017 and held it in 29 quarters.
  • Rice Hall James & Associates's Puma Biotechnology position peaked at $22.4M in Q1 2019.
  • 100 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2024.

Based on Rice Hall James & Associates's 13F filing for Q3 2024, filed 28 Oct 2024.